Tibet Rhodiola Pharmaceutical Holding Co
SSE:600211
Tibet Rhodiola Pharmaceutical Holding Co
Gross Profit
Tibet Rhodiola Pharmaceutical Holding Co
Gross Profit Peer Comparison
Competitive Gross Profit Analysis
Latest Figures & CAGR of Competitors
Company | Gross Profit | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Tibet Rhodiola Pharmaceutical Holding Co
SSE:600211
|
Gross Profit
¥3B
|
CAGR 3-Years
36%
|
CAGR 5-Years
29%
|
CAGR 10-Years
27%
|
|
Sinopharm Group Co Ltd
HKEX:1099
|
Gross Profit
¥49B
|
CAGR 3-Years
10%
|
CAGR 5-Years
11%
|
CAGR 10-Years
15%
|
|
Shanghai Pharmaceuticals Holding Co Ltd
SSE:601607
|
Gross Profit
¥31B
|
CAGR 3-Years
5%
|
CAGR 5-Years
7%
|
CAGR 10-Years
12%
|
|
Jointown Pharmaceutical Group Co Ltd
SSE:600998
|
Gross Profit
¥11.4B
|
CAGR 3-Years
4%
|
CAGR 5-Years
9%
|
CAGR 10-Years
17%
|
|
C
|
China National Medicines Corp Ltd
SSE:600511
|
Gross Profit
¥4B
|
CAGR 3-Years
8%
|
CAGR 5-Years
3%
|
CAGR 10-Years
18%
|
Huadong Medicine Co Ltd
SZSE:000963
|
Gross Profit
¥12.6B
|
CAGR 3-Years
4%
|
CAGR 5-Years
9%
|
CAGR 10-Years
15%
|
See Also
What is Tibet Rhodiola Pharmaceutical Holding Co's Gross Profit?
Gross Profit
3B
CNY
Based on the financial report for Dec 31, 2023, Tibet Rhodiola Pharmaceutical Holding Co's Gross Profit amounts to 3B CNY.
What is Tibet Rhodiola Pharmaceutical Holding Co's Gross Profit growth rate?
Gross Profit CAGR 10Y
27%
Over the last year, the Gross Profit growth was 27%. The average annual Gross Profit growth rates for Tibet Rhodiola Pharmaceutical Holding Co have been 36% over the past three years , 29% over the past five years , and 27% over the past ten years .